What is the clinical evidence from this study?

Study design: Other. Population: Lung ischemia-reperfusion injury. Intervention: Sulfatide vs. Vehicle (PBS with 0.5% polysorbate-20). Primary outcome: Lung ischemia-reperfusion injury severity.

What does this research mean for the field?

Sulfatide-reactive type II NKT cells promote M2 polarization of alveolar macrophages, alleviating lung ischemia-reperfusion injury. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to explore the role of type II NKT cells in distinct mechanisms contributing to lung ischemia-reperfusion injury.

January 20, 2026Communications Biology0 citationsOpen Access

Functional remodeling of iNKT cells by sulfatide-reactive type II NKT cells reprograms alveolar macrophages to alleviate lung ischemia-reperfusion injury

QLQ. LiWuhan University JYJ. YinWuhan University QLQibin LinSecond Affiliated Hospital of Zhejiang University

Key Result

Sulfatide-reactive type II NKT cells promoted M2 polarization of alveolar macrophages and alleviated lung ischemia-reperfusion injury via an IL-10-dependent mechanism in a mouse model.

Key Points

The study aims to explore the role of type II NKT cells in distinct mechanisms contributing to lung ischemia-reperfusion injury.
Developed a lung ischemia-reperfusion injury mouse model.
Evaluated M2 polarization of alveolar macrophages influenced by NKT cell interactions.
Analyzed the impact of interleukin-10 on macrophage gene regulation.
Sulfatide-reactive type II NKT cells significantly promoted M2 polarization of alveolar macrophages.
The protective effects against lung injury were absent in the absence of invariant NKT cells.
Interleukin-10 from NKT cells increased the expression of Arid3a and DDIT4 in macrophages.

Structured PICO

Does sulfatide administration alleviate lung ischemia-reperfusion injury in a mouse model?

Population

Male C57BL/6J (WT), Jα18-/-, and CD1d-/- mice (8-10 weeks old, 20-25g) subjected to a lung ischemia-reperfusion injury (LIRI) model (1 hour ischemia, 4 hours reperfusion).

Intervention

Sulfatide 20 μg intraperitoneal injection

Comparator

Control solution (PBS with 0.5% polysorbate-20) or sham surgery

Outcome

Lung injury assessment including lung wet/dry weight ratio, pulmonary microvascular permeability (Evans blue dye extravasation), oxidative stress (MDA levels), and oxygenation index (PaO2/FiO2)surrogate

Sulfatide-reactive type II NKT cells alleviate lung ischemia-reperfusion injury by promoting IL-10 secretion from iNKT cells, which drives M2 polarization of alveolar macrophages via the Arid3a/DDIT4 pathway.

Abstract

Lung ischemia-reperfusion injury (LIRI) is a serious complication in critical clinical situations. Despite its importance, the specific role of type II natural killer T (NKT) cells in LIRI remains unclear. In this study, we establish a LIRI mouse model and demonstrate that sulfatide-reactive type II NKT cells promote M2 polarization of alveolar macrophages (AMs) and alleviate LIRI through AMs-mediated mechanisms. This protective effect is absent in Jα18-/- mice, indicating the essential role of invariant NKT (iNKT) cells. Further analysis shows that interleukin-10 (IL-10) secreted by iNKT cells upregulates AT-rich interaction domain 3 A (Arid3a) in macrophages, which then promotes the transcription of DNA damage inducible transcript 4 (DDIT4). This cascade enhances M2 polarization of macrophages, potentially contributing to lung protection and alleviating LIRI. These findings suggest that NKT cells may offer a therapeutic target for LIRI in the future.

问 AI

Bookmark

View Full Paper